These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 30080294)

  • 1. Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases.
    Abenavoli L; Izzo AA; Milić N; Cicala C; Santini A; Capasso R
    Phytother Res; 2018 Nov; 32(11):2202-2213. PubMed ID: 30080294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Milk thistle in liver diseases: past, present, future.
    Abenavoli L; Capasso R; Milic N; Capasso F
    Phytother Res; 2010 Oct; 24(10):1423-32. PubMed ID: 20564545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of milk thistle (Silybum marianum) and its main flavonolignans on CYP2C8 enzyme activity in human liver microsomes.
    Albassam AA; Frye RF; Markowitz JS
    Chem Biol Interact; 2017 Jun; 271():24-29. PubMed ID: 28457856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.)-Chemistry, Bioavailability, and Metabolism.
    Bijak M
    Molecules; 2017 Nov; 22(11):. PubMed ID: 29125572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years.
    Federico A; Dallio M; Loguercio C
    Molecules; 2017 Jan; 22(2):. PubMed ID: 28125040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations.
    Brantley SJ; Oberlies NH; Kroll DJ; Paine MF
    J Pharmacol Exp Ther; 2010 Mar; 332(3):1081-7. PubMed ID: 19934397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The study of flavonolignan association patterns in fruits of diverging Silybum marianum (L.) Gaertn. chemotypes provides new insights into the silymarin biosynthetic pathway.
    Martinelli T; Whittaker A; Benedettelli S; Carboni A; Andrzejewska J
    Phytochemistry; 2017 Dec; 144():9-18. PubMed ID: 28863306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silybum marianum (milk thistle) and its main constituent, silymarin, as a potential therapeutic plant in metabolic syndrome: A review.
    Tajmohammadi A; Razavi BM; Hosseinzadeh H
    Phytother Res; 2018 Oct; 32(10):1933-1949. PubMed ID: 30015401
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Nawaz A; Zaib S; Khan I; Ahmed A; Shahzadi K; Riaz H
    Anticancer Agents Med Chem; 2023; 23(13):1519-1534. PubMed ID: 37055902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotaxonomic and biosynthetic relationships between flavonolignans produced by Silybum marianum populations.
    AbouZid SF; Ahmed HS; Moawad AS; Owis AI; Chen SN; Nachtergael A; McAlpine JB; Brent Friesen J; Pauli GF
    Fitoterapia; 2017 Jun; 119():175-184. PubMed ID: 28392269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the analysis of flavonolignans of Silybum marianum.
    Csupor D; Csorba A; Hohmann J
    J Pharm Biomed Anal; 2016 Oct; 130():301-317. PubMed ID: 27321822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemistry of silybin.
    Biedermann D; Vavříková E; Cvak L; Křen V
    Nat Prod Rep; 2014 Sep; 31(9):1138-57. PubMed ID: 24977260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recapitulation of Evidence of Phytochemical, Pharmacokinetic and Biomedical Application of Silybin.
    Islam A; Mishra A; Siddiqui MA; Siddiquie S
    Drug Res (Stuttg); 2021 Nov; 71(9):489-503. PubMed ID: 34318464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos).
    Kidd P; Head K
    Altern Med Rev; 2005 Sep; 10(3):193-203. PubMed ID: 16164374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Cytotoxicity and Genotoxicity of Flavonolignans in Different Cellular Models.
    Bijak M; Synowiec E; Sitarek P; Sliwiński T; Saluk-Bijak J
    Nutrients; 2017 Dec; 9(12):. PubMed ID: 29240674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review.
    Soleimani V; Delghandi PS; Moallem SA; Karimi G
    Phytother Res; 2019 Jun; 33(6):1627-1638. PubMed ID: 31069872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silymarin and hepatocellular carcinoma: a systematic, comprehensive, and critical review.
    Mastron JK; Siveen KS; Sethi G; Bishayee A
    Anticancer Drugs; 2015 Jun; 26(5):475-86. PubMed ID: 25603021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silymarin: not just another antioxidant.
    Camini FC; Costa DC
    J Basic Clin Physiol Pharmacol; 2020 Mar; 31(4):. PubMed ID: 32134732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silymarin and Its Role in Chronic Diseases.
    Neha ; Jaggi AS; Singh N
    Adv Exp Med Biol; 2016; 929():25-44. PubMed ID: 27771919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene Expression Analysis and Metabolite Profiling of Silymarin Biosynthesis during Milk Thistle (
    Drouet S; Tungmunnithum D; Lainé É; Hano C
    Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32630801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.